Skip to main content
SpringerLink
Log in

Pharmakokinetik subkutan injizierten Insulins

  • Chapter
Praxis der Insulintherapie

  • 95 Accesses

Zusammenfassung

Die molekularbiologischen Vorgänge der Absorption von Insulin in die Blutbahn nach der subkutanen Injektion der Hormonlösung sind bis heute nicht endgültig geklärt. Die Erweiterung der Kenntnisse über die Kinetik des Absorptionsvorganges hat jedoch für die klinische Praxis eine zunehmende Bedeutung gewonnen. Heute wird der Absorptionsprozeß zumeist mittels des Schemas der Abb. 11 beschrieben. Dabei geht man davon aus, daß ein erheblicher (und modifizierbarer) Anteil der Verzögerung des Absorptionsvorganges nach der subkutanen Insulininjektion durch die Dissoziation der in handelsüblichen Lösung vorliegenden Insulin-Hexa- mere bedingt ist.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 54.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Berger M, Cüppers HJ, Hegner H, Jörgens V, Berchtold P (1982) Absorption kinetics and biological effects of subcutaneously injected insulin preparations. Diabetes Care 5:77–91

    Article  PubMed  CAS  Google Scholar 

  • Heinemann L, Berger M (2000) Insulintherapie. In: Berger M (Hrsg.) Diabetes mellitus, 2. Auflage. Urban & Fischer, München, Jena, pp. 125–149

    Google Scholar 

  • Starke AAR, Heinemann L, Hohmann A, Berger M (1989) The action profiles of human insulin preparations. Diabetic Medicine 6:239–244

    Article  PubMed  CAS  Google Scholar 

  • Berger M, Cüppers HJ, Hegner H, Jörgens V, Berchtold P (1982) Absorption kinetics and biological effects of subcutaneously injected insulin preparations. Diabetes Care 5:77–91

    Article  PubMed  CAS  Google Scholar 

  • Kemmer FW, Berchtold P, Berger M et al (1980) Exercise-induced fall of blood glucose in insulin-treated diabetics unrelated to alteration of insulin mobilisation. Diabetes 28:1131–1137

    Google Scholar 

  • Thow JC, Johnson AB, Antsiferov M, Home PO (1989) Exercise augments the absorption of isophane (NPH) insulin. Diabetic Medicine 6:342–345

    Article  PubMed  CAS  Google Scholar 

  • Frid A, Linden B (1986) Where do lean diabetics inject their insulin? A study using computed tomography. Br Med J 292:1638

    Article  CAS  Google Scholar 

  • Spraul M, Chantelau E, Koumoulidou J, Berger M (1988) Subcutaneous or nonsubcutaneous injection of insulin. Diabetes Care 11:733–736

    PubMed  CAS  Google Scholar 

  • Vaag A, Handberg A, Lauritzen M (1990) Variation in absorption of NPH insulin due to intramuscular injection. Diabetes Care 13:74–76

    Article  PubMed  CAS  Google Scholar 

  • Berger M (1987) Human insulin — much ado about hypoglycemia (un)awareness. Diabetologia 30:829–833

    Article  PubMed  CAS  Google Scholar 

  • Chantelau EA, Lee DM, Hemmann D et al (1991) What makes insulin injections painful? Brit Med J 303:26–27

    Article  PubMed  CAS  Google Scholar 

  • Colagiuri S, Miller JJ, Petocz P (1992) Double-blind crossover comparison of human and porcine insulins in patients reporting lack of hypoglycaemia awareness. Lancet 339:1432–1435

    Article  PubMed  CAS  Google Scholar 

  • Mühlhauser I, Todt G, Sawicki PT, Berger M (1991) Hypoglycemic symptoms and frequency of severe hypoglycemia in patients treated with human and animal insulin preparations. Diabetes Care 14:745–749

    Article  PubMed  Google Scholar 

  • Sonnenberg GE, Berger M (1983) Human insulin — much ado about one amino acid? Diabetologia 25:457–459

    Article  PubMed  CAS  Google Scholar 

  • Overmann H, Heinemann I (1999) Injection-time interval: recommendations of diabetologists and how patients handle it. Diab Res Clin Pract 43:137–142

    Article  CAS  Google Scholar 

  • Scheen AJ, Letiexhe MR, Scheen, Lefèbvre PJ (1999) Minimal influence of the time interval between injection of regular insulin and food intake on blood glucose control of Type 1 diabetic patients on a basal-bolus insulin scheme. Diabetes & Metabolism. 25:157–162

    CAS  Google Scholar 

  • Berger M, Heinemann L (1997) Are presently available insulin analogues clinically beneficial? Diabetologia 40(suppl 2):91-S96

    Article  Google Scholar 

  • Bolli GB, Di Marchi RD, Park GD, Pramming S, Koivisto VA (1999) Insulin analogues and their potential in the management of diabetes mellitus. Diabetologia 42:1151–1167

    Article  PubMed  CAS  Google Scholar 

  • Brunelle RL, Llewelyn J, Anderson H jr et al (1998) Meta-analysis of the effect of insulin lispro on severe hypoglycemia in patients with Type 1 diabetes. Diabetes Care 21: 1726–1731

    Article  PubMed  CAS  Google Scholar 

  • Brunner GA, Hirschberger S, Sendlhofer G, Wutte A, Ellmerer M, Balent B, Schaupp L, Krejs GJ, Pieber TR (2000) Post-prandial administration of the insulin analogue aspartat in patients with type 1 diabetes mellitus. Diabetic Medicine 17:371–375

    Article  PubMed  CAS  Google Scholar 

  • Buse J (2000) Insulin glargine. First responsibilities: understanding the data and ensuring safety. Diabetes Care 23:576–578

    Article  PubMed  CAS  Google Scholar 

  • Davey P, Grainger D, MacMillan J et al (1997) Clinical outcome with insulin lispro compared with human regular insulin: a meta-analysis. Clin Ther 19:656–674

    Article  PubMed  CAS  Google Scholar 

  • Heinemann L, Heise T, Wahl LC et al (1996) Prandial glycaemia after a carbohydrate-rich meal in Type 1 diabetic patients: using the rapid acting insulin analogue [Lys(B28), Pro(B29)] human insulin. Diabetic Medicine 13:625–629

    Article  PubMed  CAS  Google Scholar 

  • Holleman F et al (1996) Comparison of Lys(B28), Pro(B29)-human insulin analog and regular human insulin in the correction of incidental hyperglycemia Diabetes Care 19:1426–1429

    Article  PubMed  CAS  Google Scholar 

  • Jorgensen LN, Dideriksen LH, Drejer K (1992) Carcinogenic effect of human insulin analogue BlOAsp in female rats, (abst.) Diabetologia 35 (suppl. 1):A3

    Google Scholar 

  • Kitzmiller JL, Main E, Ward B et al (1999) Insulin Lispro and the development of proliferative diabetic retinopathy during pregnancy (letter) Diabetes Care 22:874–876

    Article  PubMed  CAS  Google Scholar 

  • Kotsanos JG, Vignati L, Huster W et al (1997) Health-related quality-of-life results from multinational clinical trials of insulin lispro Diabetes Care 20:948–958

    Article  PubMed  CAS  Google Scholar 

  • Lalli C, Ciofetta M, Del Sindaco P et al (1999) Long-term intensive treatment of Type 1 diabetes with the short-acting insulin analog lispro in variable combination with NPH insulin at mealtime Diabetes Care 22:468–477

    Article  PubMed  CAS  Google Scholar 

  • Mühlhauser I, Chantelau EA, Jansen M et al (1991) Are there common features of insulin substitution strategies among C-peptide negative diabetic patients who maintain normal glycosylated haemoglobin values? Diab Nutr Metab 4:17–22

    Google Scholar 

  • Nielsen FS, Jørgensen LN, Ipsen M et al(1995) Long-term comparison of human insulin analogue BlOAsp and soluble human insulin in IDDM patients on an basal/bolus insulin regimen Diabetologia 38:592–598

    Article  PubMed  CAS  Google Scholar 

  • Renner R, Pfützner A, Trautmann M et al(1999) Use of insulin lispro in continuous subcutaneous insulin infusion treatment Diabetes Care 22:784–788

    Article  PubMed  CAS  Google Scholar 

  • Zinman B, Tildesley H, Chiasson JL, Tsui E, Strack T (1997) Insulin-lispro in CSII. Results of a double-blind cross-over study Diabetes 46:440–443

    Article  PubMed  CAS  Google Scholar 

  • Berger M (2000) Safety of insulin glargine. Lancet 356:2013–2014

    Article  PubMed  CAS  Google Scholar 

  • Home P (1999) Insulin glargine: the first clinically useful extended-acting insulin in half a century? Exp Opin Invest Drugs 8:307–314

    Article  CAS  Google Scholar 

  • Kurtzhals P, Schäffer L, Sorensen A, Kristensen C, Jonassen lb, Schmid C, Trüb T (2000) Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use Diabetes 49:999–1005

    Article  PubMed  CAS  Google Scholar 

  • Heinemann L, Breuer Z, Cebulla D et at (1996) Wirkungsprofile von Normalinsulin, NPH- Insulin sowie einer 25/75 Mischung hergestellt aus gentechnologischem bzw. semisynthetischem Humaninsulin. Diabetes Stoffw 5:157–163

    Google Scholar 

  • Heinemann L, Linkeschova, R, Rave K, Hompesch B, Sedlak, M, Heise T (2000) TimeAction profile of long-acting insulin analog insulin glargine (Hoe 901) in comparison with those of insulin and placebo. Diabetes Care 23:644–649

    Article  PubMed  CAS  Google Scholar 

  • Pieber TR, Eugene-Jolchine I, Derobert E, the European Study Group of HOE 901 in Type 1 Diabetes (2000) Efficacy and safety of HOE 901 versus NPH insulin in patients with type 1 diabetes. Diabetes Care 23:157–162

    Article  PubMed  CAS  Google Scholar 

  • Ratner RE, Hirsch IB, Neifing JL, Garg SK, Mecca TE, Wilson CA, for the U.S. Study Group of Insulin Glargine in Type 1 Diabetes (2000) Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. Diabetes Care 23:639–643

    Article  PubMed  CAS  Google Scholar 

  • Yki-Järvinen H, Dressier A, Ziemen M et al (2000) Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. Diabetes Care 23:1130–1136

    Article  PubMed  Google Scholar 

  • Heinemann L, Berger M (2000) Insulintherapie. In: Berger M (Hrsg) Diabetes mellitus, 2. Aufl. Urban & Fischer, München Jena, pp 125–149

    Google Scholar 

  • Davidson JK, Anderson JHJ, Chance RE (2000) Insulin therapy. In: Davidson JK (ed) Clinical diabetes mellitus. A problem-oriented approach, 3rd edn. Thieme-Stratton, New York, pp 329–404

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik für Stoffwechselkrankheiten und Ernährung WHO Collaborating Centre for Diabetes, Heinrich-Heine-Universität Düsseldorf, Moorenstraße 5, 40225, Düsseldorf, Deutschland

    Professor Dr. med. Dres. h.c. mult. Michael Berger & Dr. med. Viktor Jörgens

Authors
  1. Professor Dr. med. Dres. h.c. mult. Michael Berger
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dr. med. Viktor Jörgens
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2001 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Berger, M., Jörgens, V. (2001). Pharmakokinetik subkutan injizierten Insulins. In: Praxis der Insulintherapie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-97548-6_5

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-97548-6_5

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-57468-2

  • Online ISBN: 978-3-642-97548-6

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation